Dopamine receptor D1 (DRD1) and Dopamine receptor D5 (DRD5) (D1/D5 receptors)

The Dopamine receptor D1 and D5, collectively referred to as the D1-like receptor family, are essential G protein-coupled receptors (GPCRs) primarily involved in stimulatory signaling within the central nervous system and various peripheral tissues (Source: UniProt P21728, P21918). Unlike the D2-like family, D1 and D5 receptors are coupled to Gs or Golf proteins, which activate adenylate cyclase and increase intracellular cyclic AMP (cAMP) levels (Source: StatPearls, Dopamine Receptors). In the brain, these receptors are densely located in the striatum, prefrontal cortex, and hippocampus, where they play critical roles in modulating motor activity, executive function, and reward processing (Source: PubMed PMID: 21939638). Peripherally, they are expressed in the kidneys and blood vessels, contributing to the regulation of renal blood flow and sodium excretion (Source: PubChem, Fenoldopam). Dysregulation of D1/D5 signaling is implicated in several neurological and psychiatric conditions, including Parkinson's disease, schizophrenia, and attention deficit hyperactivity disorder (ADHD) (Source: NIH, Gene ID: 1812). Pharmacological targeting of these receptors includes the use of agonists like fenoldopam for hypertensive emergencies and the development of selective partial agonists like tavapadon for Parkinson's disease (Source: Wikipedia, Dopamine receptor D1). However, achieving high selectivity between D1 and D5 remains a significant challenge in drug discovery due to their high structural homology (Source: IUPHAR/BPS Guide to Pharmacology).

Other names

D1-like dopamine receptorsDRD1DRD5D1RD5RDopamine D1 receptorDopamine D5 receptor

D1 and D5 receptors function by coupling to stimulatory G proteins (Gs or Golf), which activate the enzyme adenylate cyclase to increase the production of the second messenger cyclic adenosine monophosphate (cAMP) (Source: StatPearls). This increase in cAMP subsequently activates protein kinase A (PKA) and other downstream signaling pathways that modulate neuronal excitability and gene expression (Source: UniProt). Drugs targeting these receptors act as agonists to enhance this stimulatory signaling, which is beneficial in treating motor deficits, or as antagonists to reduce overactive signaling in conditions like psychosis (Source: PubChem).